Close

BioLineRx (BLRX), Genentech Enter Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab

Go back to BioLineRx (BLRX), Genentech Enter Research Collaboration to Investigate Combination of BL-8040 with Atezolizumab

Roth Positive on BioLineRx (BLRX) Amid Latest BL-8040 Phase 2a Data in r/r AML

September 8, 2016 9:59 AM EDT

Roth Capital affirms its Buy rating and $7 price target on BioLineRx Ltd. (Nasdaq: BLRX) after the company announced the presentation of successful final results of BL-8040's Phase 2a clinical trial in relapsed or refractory acute myeloid leukemia (r/r AML).

Analyst Joseph Pantginis commented today, The final r/r AML data continue to point to a bright path forward... More